No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PBH Prestige Consumer Healthcare
- 67.320
- -0.960-1.41%
Close Jul 3 13:00 ET
- 67.550
- +0.230+0.34%
Post 14:50 ET
3.36BMarket Cap16.14P/E (TTM)
68.500High67.200Low134.55KVolume68.500Open68.280Pre Close9.09MTurnover0.27%Turnover Ratio16.14P/E (Static)49.92MShares75.31052wk High2.03P/B3.33BFloat Cap56.34452wk Low--Dividend TTM49.49MShs Float75.310Historical High--Div YieldTTM1.90%Amplitude3.920Historical Low67.550Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Prestige Consumer Healthcare to Release Fiscal 2025 First Quarter Earnings Results
PDF VersionTARRYTOWN, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 first quarter earnings release on Thursd
This Nike Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Express News | Prestige Consumer Healthcare Inc : D.a. Davidson Raises to Buy From Neutral
D.A. Davidson Upgrades Prestige Consumer Healthcare(PBH.US) to Buy Rating, Announces Target Price $93
D.A. Davidson analyst Linda Bolton Weiser upgrades $Prestige Consumer Healthcare(PBH.US)$ to a buy rating, and sets the target price at $93.According to TipRanks data, the analyst has a success rate o
Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Business Is Trailing The Industry But Its Shares Aren't
It's not a stretch to say that Prestige Consumer Healthcare Inc.'s (NYSE:PBH) price-to-sales (or "P/S") ratio of 2.9x right now seems quite "middle-of-the-road" for companies in the Pharmaceuticals i
Prestige Consumer Healthcare (PBH) Down 0.4% Since Last Earnings Report: Can It Rebound?
Comments
Investors seem to focus more on the company's revenue growth despite the decrease in earnings per share. The company's long-term track record of an annual TSR of 20% over five years makes it a business worth watching.
Those Who Invested in Prestige Consumer Healthcare (NYSE:PBH) Five Years Ago Are up 144% 1
Investors may be expecting a turnaround in the company's lackluster revenue performance, hence the moderate P/S ratio. However, the company's muted revenue growth estimates compared to the industry make its current P/S ratio unexpected. A positive change is needed to justify this ratio.
1
Prestige Consumer Healthcare's revenue growth is predicted to slow, with an estimated annual growth rate of 1.9% until 2025, significantly below the historical 4.2% p.a. growth. Compared to industry peers forecasted to grow at 9.0% per year, Prestige is expected to lag behind.
An insider selling shares below the current price may suggest they deemed the lower price fair, questioning their view of the recent higher valuation. However, this is a weak sign as it doesn't imply insiders think the shares are fully valued. The level of insider ownership indicates a reasonable alignment with shareholder interests.
Gainers:
• $Biohaven(BHVN.US$ +70.3% (Biohaven Pharmaceutical and Pfizer (PFE) announce that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven)
• $Vroom(VRM.US$ +33.3% (also CEO Paul Hennessy steps down; Tom Shortt appointed as CEO)
• $Nuvve(NVVE.US$ +10.2% (NVVE and CENN announce alliance to offer electrification solution for commercial fleets)
• $ShockWave Medical(SWAV.US$ +14.6% (I...
• $Biohaven(BHVN.US$ +70.3% (Biohaven Pharmaceutical and Pfizer (PFE) announce that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven)
• $Vroom(VRM.US$ +33.3% (also CEO Paul Hennessy steps down; Tom Shortt appointed as CEO)
• $Nuvve(NVVE.US$ +10.2% (NVVE and CENN announce alliance to offer electrification solution for commercial fleets)
• $ShockWave Medical(SWAV.US$ +14.6% (I...
20
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg